As part of our purpose to serve overlooked patients, we’re sharing that an FDA-approved ready-to-use oral solution for treating ADHD in adults and pediatric patients 6 years and older will be available mid-2026. #overlookedpatients#ADHD Learn more: bit.ly/4quaiHV
BREAKING NEWS: ACA Pharma Named Exclusive Distributor for Ferabright™ in Macau, Hong Kong, Singapore, Greater Bay Area & Mainland China
hashtag #overlookedpatientsazurity.com/aca-pharma-named…
We're heading to Las Vegas, NV for the 2025 ASHP Midyear Clinical Meeting (December 8-10). Come visit us at Booth #654 to learn more about how Azurity is serving overlooked patients. #ASHP25#OverlookedPatients
We're heading to Chicago, IL for the 2025 Radiological Society of North America annual meeting (Nov 30-Dec 4). Come visit us at Booth #3578 to learn more about how Azurity is serving overlooked patients. #RSNA25#OverlookedPatients
BREAKING NEWS: Azurity Pharmaceuticals Announces the FDA Approval of Ferabright™ (ferumoxytol injection), the First and Only Iron-Based Contrast Agent Indicated for Magnetic Resonance Imaging of the Brain #overlookedpatients#MRIazurity.com/azurity-pharmace…